Home › Alpha-1 Antitrypsin Deficiency › Ohio › Cleveland
Alpha-1 Antitrypsin Deficiency clinical trials in Cleveland, OH
3 studies for Alpha-1 Antitrypsin Deficiency are looking for participants at sites in and around Cleveland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
RecruitingPhase 3
- GC2501 Study Site 104, Cleveland
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
RecruitingPhase 3
- University Hospitals Cleveland Medical Center, Cleveland
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
RecruitingPhase 3
- University Hospitals Cleveland Medical Center, Cleveland
About Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency is an inherited condition that raises your risk for lung and liver disease. Learn about the symptoms and treatment.
More about Alpha-1 Antitrypsin Deficiency on MedlinePlus
Alpha-1 Antitrypsin Deficiency trials in other cities
- Gainesville, FL6 studies
- Charleston, SC6 studies
- Birmingham, AL5 studies
- New York City, NY4 studies
- Boston, MA4 studies
- Rochester, MN4 studies
- Phoenix, AZ3 studies
- Los Angeles, CA3 studies
- Miami, FL3 studies
Other studies in Cleveland
- Non-Small Cell Lung Cancer43 studies
- Cancer (all types)36 studies
- Breast Cancer35 studies
- Prostate Cancer34 studies
- Heart Failure33 studies
- Metastatic Cancer30 studies
- Ovarian Cancer30 studies
- Lung Cancer26 studies
- Colorectal Cancer24 studies
- Cardiovascular Disease22 studies
- Endometrial Cancer20 studies
- Acute Myeloid Leukemia20 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.